Navigation Links
Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
Date:11/3/2010

GAITHERSBURG, Md., Nov. 3, 2010 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

Only companies with no more than 250 employees were eligible. Qualifying projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, reduce long-term healthcare costs in the U.S., or significantly advance the goal of curing cancer within a 30-year period. 

In addition, preference was given to projects that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country's competitiveness in the fields of life, biological, and medical sciences. Qualifying projects were eligible for either grants or tax credits.

"We are very pleased that 8 of the 9 applications that we submitted for review by the NIH and Treasury were approved and that the overall grant placed us among the top 5% of recipients in the nation. This provides further validation of our programs in cell therapies, vaccines and biotherapeutics," stated Tim Ravenscroft, CEO of Lentigen.  "As a small company operating in a difficult economic climate, these funds are very timely and will be invested in completion of our GMP manufacturing facility and the support of several of the therapeutic and vaccine programs submitted for consideration."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, IAVI, Harvard Medical School, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The Johns Hopkins University, Case Western Reserve University, The Medical College of South Carolina, The University of Pittsburgh, the University of Minnesota, and The U.S. Army. For further information, visit www.lentigen.com.


'/>"/>
SOURCE Lentigen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Awarded Phase I STTR Grant for Hunter Syndrome
2. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
3. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
4. Lentigen Corporation Announces Relocation to New Facility
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
8. Federal nanotechnology renewal grant awarded to ASU faculty
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. LSU researchers awarded 1 of the largest NSF grants in Louisiana history
11. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight ... nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. , ... in two categories, one for experiment and the other for theory in nanotechnology. ...
(Date:5/20/2016)... ... 20, 2016 , ... Kablooe Design, a leading provider of product design and ... anniversary of the business. “We have worked hard to build long-term relationships,” says President ... privilege and honor of serving their product design and development needs through the years.” ...
(Date:5/19/2016)... Virginia (PRWEB) , ... May 19, 2016 , ... Anton ... new 30,000 square foot office building is complete. The new structure adds a third ... 2011, Anton Paar USA purchased 2.4 acres of land, along with office ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
Breaking Biology News(10 mins):